The global skeletal dysplasia market is anticipated to grow with a modest growth rate during the forecast period. The skeletal dysplasia disorder is a heterogeneous group of more than 350 disorders found in both adults and children. Skeletal dysplasia is frequently associated with orthopedic complications and varying degrees of dwarfism or short stature.
It is a rare disease and is observed in 2.4 per 10,000 births (as per the Johns Hopkins University). Skeletal dysplasia disorder also affects significant number of young children. The severity of the disorder is very high in children as along with the various orthopedic problems they also suffer from a frequent chest infection, hearing, and breathing difficulty. The growth of the skeletal dysplasia market is attributed to the advancements in the understanding of the pathophysiology of skeletal dysplasia that is propelling the efforts in treatment strategies. Additionally, emerging new advanced drug therapy for the treatment of skeletal dysplasia will also fuel the skeletal dysplasia market industry.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/skeletal-dysplasia-market
These increasing variety of medical and surgical treatment options for the treatment of skeletal dysplasia is aiding significantly to the improved quality of life and increased lifespan of the patients. Since the quality of life is severely affected by spinal and orthopedic disorders. Hence, a considerable increase in the adoption of treatment is anticipated during the forecast period.
Moreover, the skeletal dysplasia disorder’s diagnosis based on various radiographic, clinical, and molecular criteria and the continuous improvement in the clinical diagnosis is increasing the number of diagnosed cases. This in turn is fuelling the skeletal dysplasia growth. For instance, in December 2019, Invitae Corp. launched “Discover Dysplasias”. It is an initiative with BioMarin Pharmaceutical Inc. for genetic testing at no charge to patients with symptoms of having a skeletal dysplasia. Furthermore, several surgical therapies are also being attempted to correct bone deformities in patients with skeletal dysplasia. In addition to this, the increasing number of clinical trials of growth hormone (GH) therapy for patients with skeletal dysplasia disorder is anticipated to considerably drive the skeletal dysplasia market.
A full report of Global Skeletal Dysplasia Market available @ https://www.omrglobal.com/industry-reports/skeletal-dysplasia-market
Skeletal Dysplasia Market Segmentation
By Type
- Achondroplasia
- Thanatophoric dysplasia
- Hypochondroplasia
- Others
By Treatment
- Medications
- Therapy
- Others (Surgery)
Regional Analysis
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
